"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 3 | 5 |
| 1999 | 2 | 1 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 1 | 2 |
| 2017 | 4 | 2 | 6 |
| 2018 | 5 | 2 | 7 |
| 2019 | 9 | 1 | 10 |
| 2020 | 8 | 2 | 10 |
| 2021 | 9 | 0 | 9 |
| 2022 | 5 | 1 | 6 |
| 2023 | 4 | 2 | 6 |
| 2024 | 5 | 2 | 7 |
| 2025 | 5 | 1 | 6 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Brief Report: Long-Acting Injectable PrEP Can Substantially Reduce HIV Incidence in Los Angeles County: A Simulation Study. J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):273-278.
-
Higher Acceptability of the Monthly Dapivirine Ring Versus Daily Oral Pre-Exposure Prophylaxis Among Adolescent Girls and Young Women in Sub-Saharan Africa in the REACH Trial. J Acquir Immune Defic Syndr. 2025 Dec 15; 100(5):415-424.
-
Pharmacy HIV pre-exposure prophylaxis/post-exposure prophylaxis furnishing: The benefits of collaborating with peer navigators. J Am Pharm Assoc (2003). 2026 Jan-Feb; 66(1):102978.
-
Measuring Pre-Exposure Prophylaxis (PrEP) Stigma Among Adolescent Girls and Young Women in Western Kenya: Scale Development, Validation, and Associations with PrEP Adherence. AIDS Patient Care STDS. 2025 Aug; 39(8):323-338.
-
Longer-acting preexposure prophylaxis product and delivery preferences among U.S. populations disproportionately affected by HIV: a discrete choice experiment. AIDS. 2025 Aug 01; 39(10):1364-1374.
-
Lessons Learned From Engaging Healthcare Providers in Research on Implementation of HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2025 Apr 15; 98(5S):e129-e135.
-
Applying implementation science frameworks to understand why fisherfolk continue or discontinue pre-exposure prophylaxis for HIV prevention in Uganda: a qualitative analysis. BMJ Glob Health. 2025 Jan 22; 10(1).
-
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 03; 392(13):1261-1276.
-
A Qualitative Assessment of South Africa's Central Chronic Medication Dispensing and Distribution Program for Differentiated Antiretroviral Therapy Delivery in Umlazi Township, South Africa: Client Perspectives after 12 Months of Participation. AIDS Behav. 2025 Feb; 29(2):673-683.
-
A Pilot Study of a Sibling-Based Online Intervention to Increase PrEP Uptake and Willingness Among Latino MSM. AIDS Educ Prev. 2024 Oct; 36(5):299-323.